Maibo Pharmaceutical-B (02181) announced its 2023 results, with revenue of about 87.161 million yuan, a year-on-year increase...
According to Zhitong Finance App, Maibo Pharmaceutical-B (02181) announced its 2023 results, with operating income of about 87.161 million yuan, up 55.9% year on year; gross profit of 75.238 million yuan, up 85.6% year on year; R&D expenses of about 123 million yuan, a decrease of 16.7% year on year; total losses and overall expenses due to company owners were about 209 million yuan, a decrease of 0.7% year on year; loss per share was 0.05 yuan.
According to the announcement, the increase in revenue was mainly due to a sharp increase in drug sales revenue during the reporting period compared to last year. The reduction in R&D expenses for drugs under development is mainly due to the completion of clinical trials for core products.